Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Post by narcissiston Oct 05, 2011 10:28am
517 Views
Post# 19120734

NEWS: Voclosporin study published in the American

NEWS: Voclosporin study published in the American

Voclosporin study published in the American Journal of Transplantation


Conclusions:

"The AJT is the highest impact journal in the field of transplantation,and we are very pleased to have voclosporin featured in such aprestigious publication.  Calcineurin inhibitors (currentlycyclosporine and TAC) remain the cornerstone of immunosuppressanttherapy for transplant patients.  NODAT is an important concern withTAC.  The literature demonstrates that NODAT results in increased graftloss by 3 years, a 23% increase in patient death at 5 years, with anannual cost of $12,0001,2,3.  We anticipate that our novel calcineurin inhibitor, voclosporin, willprovide a significant benefit in this regard, as well as cause lessdiarrhea and tremors.  Furthermore, the clear relationship betweenblood concentrations of voclosporin and clinical outcomes  withvoclosporin is another distinct advantage as it should enhance ease ofdosing and monitoring for both physicians and patients," commented Dr.Robert Foster, CEO of Isotechnika.
<< Previous
Bullboard Posts
Next >>